Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals

Nat Med. 2021 Aug;27(8):1367-1369. doi: 10.1038/s41591-021-01407-5. Epub 2021 Jun 10.

Abstract

Mass vaccination has the potential to curb the current COVID-19 pandemic by protecting individuals who have been vaccinated against the disease and possibly lowering the likelihood of transmission to individuals who have not been vaccinated. The high effectiveness of the widely administered BNT162b vaccine from Pfizer-BioNTech in preventing not only the disease but also infection with SARS-CoV-2 suggests a potential for a population-level effect, which is critical for disease eradication. However, this putative effect is difficult to observe, especially in light of highly fluctuating spatiotemporal epidemic dynamics. Here, by analyzing vaccination records and test results collected during the rapid vaccine rollout in a large population from 177 geographically defined communities, we find that the rates of vaccination in each community are associated with a substantial later decline in infections among a cohort of individuals aged under 16 years, who are unvaccinated. On average, for each 20 percentage points of individuals who are vaccinated in a given population, the positive test fraction for the unvaccinated population decreased approximately twofold. These results provide observational evidence that vaccination not only protects individuals who have been vaccinated but also provides cross-protection to unvaccinated individuals in the community.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 / prevention & control*
  • COVID-19 / virology
  • COVID-19 Vaccines / immunology*
  • Humans
  • SARS-CoV-2 / immunology*

Substances

  • COVID-19 Vaccines